144163-68-8

Basic information

• Product Name: N-Methylthiazole-2-methanamine
• Synonyms: METHYL-THIAZOL-2-YLMETHYL-AMINE;N-Methyl-[(1,3-thiazol-2-yl)methyl]amine;N-Methylthiazole-2-methanamine;2-Methylaminomethylthiazole;N-methyl-1-(1,3-thiazol-2-yl)methanamine(SALTDATA: 2HCl);N-Methyl-1-(1,3-thiazol-2-yl)methanamine dihydrochloride;N-Methyl-1-(thiazol-2-yl)MethanaMine
• CAS NO: 144163-68-8
• Molecular Formula: C₅H₈N₂S
• Molecular Weight: 128.2
• Mol File: 144163-68-8.mol

Chemical Properties

• Boiling Point: 181.371 °C at 760 mmHg
• Flash Point: 63.491 °C
• Appearance: /
• Density: 1.127 g/cm³
• Vapor Pressure: 0.855mmHg at 25°C
• Refractive Index: 1.543
• PKA: 7.44±0.10(Predicted)
• CAS DataBase Reference: N-Methylthiazole-2-methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methylthiazole-2-methanamine(144163-68-8)
• EPA Substance Registry System: N-Methylthiazole-2-methanamine(144163-68-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 144163-68-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Methylthiazole-2-methanamine is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique structure allows it to be a versatile building block, enabling the creation of various compounds with different therapeutic properties.
Used in Chemical Synthesis:
In the chemical synthesis industry, N-Methylthiazole-2-methanamine is used as a versatile intermediate. Its ability to undergo reactions such as alkylation and acylation makes it suitable for the production of a wide range of compounds with diverse applications.
Used in Research and Development:
MTMA is utilized in research and development for its potential biological activities and pharmacological properties. Its unique structure and reactivity make it a promising candidate for the discovery of new therapeutic agents and other applications in the scientific community.

InChI:InChI=1/C5H8N2S/c1-6-4-5-7-2-3-8-5/h2-3,6H,4H2,1H3

Upstream product

• 10200-59-6 Thiazole-2-carbaldehyde 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 1569656-51-4 C₁₈H₁₄N₄O₂S 
• 1569653-73-1 C₁₉H₁₅F₃N₄O₂S 
• 144164-00-1 {4-[3-((S)-1-{(1S,3S,4S)-1-Benzyl-2,3-dihydroxy-4-[(S)-3-methyl-2-(3-methyl-3-thiazol-2-ylmethyl-ureido)-butyrylamino]-5-phenyl-pentylcarbamoyl}-2-methyl-propyl)-1-methyl-ureidomethyl]-thiazol-2-yl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Total synthesis of micromide: A marine natural product

This paper describes an efficient procedure for the synthesis of micromide, a natural product that shows anti-solid-tumor activity. Our strategy involved the synthesis of N-nosyl-protected amino acids and their N-methylation with iodo-methane. The hindered oligopeptides containing N-methyl amino acids were synthesized in excellent yields and high purities.[ampi]]

SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS

This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administ

Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol

The structure-activity relationships in two series of novel, symmetry-based inhibitors of HIV protease, the enzyme responsible for maturation of the human immunodeficiency virus, are described.Beginning with lead compounds 3-6, the effect of adding polar, heterocyclic end groups to one or both ends of the symmetric or pseudosymmetric inhibitors was probed.Aqueous solubility was enhanced >1000-fold while maintaining potent inhibition of purified HIV-1 protease and anti-HIV activity in vitro.Pharmacokinetic studies in rats indicated a substantial difference in the absorption properties of mono-ol-based and diol-based inhibitors.The oral bioavailability of inhibitor 19 in rats was 19percent; however, the Cmax obtained failed to exceed the anti-HIV EC50 in vitro.Substantial plasma levels of potent inhibitors of the diol class were not obtained after oral administration in rats; however, the optimal combination of aqueous solubility and in vitro antiviral activity of several inhibitors support their potential use in intravenous therapy.